Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model

Molecular Cancer Therapeutics

Volumn 4, Issue 2, 2005, Pages 187-195

  Yamanaka, Kazuki ^a   Gleave, Martin E ^a   Hara, Isao ^b   Muramaki, Mototsugu ^a   Miyake, Hideaki ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANDROGEN; ANTISENSE OLIGODEOXYNUCLEOTIDE; CLUSTERIN; MESSENGER RNA; MITOXANTRONE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; FEMALE; GENE EXPRESSION REGULATION; GENE TARGETING; GENE TRANSFER; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; LYMPH NODE METASTASIS; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR CELL LINE; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANDROGENS; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CLUSTERIN; COMBINED MODALITY THERAPY; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, P53; GENETIC VECTORS; GLYCOPROTEINS; HUMANS; LYMPHATIC METASTASIS; MALE; MICE; MITOXANTRONE; MOLECULAR CHAPERONES; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PROSTATIC NEOPLASMS; RNA, MESSENGER;

EID: 14844293486     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Denis L, Murphy GP. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 1993;72: 3888-95.
2. Oh WK, Kantoff PW. Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 1998;160: 1220-9.
3. Haviv YS, Curiel DT. Conditional gene targeting for cancer gene therapy. Adv Drug Deliv Rev 2001;53:135-54.
4. Welsh MJ, Smith AE, Zabner J, et al. Cystic fibrosis gene therapy using an adenovirus vector: in vivo safety and efficacy in nasal epithelium. Hum Gene Ther 1994;5:209-19.
5. Horowitz J. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications. Curr Opin Mol Ther 1999;1:500-9.
6. Zhang WW, Fang X, Mazur W, French BA, Georges RN, Roth JA. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1994;1:1-10.
7. Spitz FR, Nguyen D, Skibber JM, Meyn RE, Cristiano RJ, Roth JA. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res 1996;2:1665-71.
8. Miyake H, Hara I, Hara S, Arakawa S, Kamidono S. Synergistic chemosensitization and inhibition of tumor growth and metastasis by adenovirus-mediated p53 gene transfer in human bladder cancer model. Urology 2000;56:332-6.
9. Harrington KJ, Spitzweg C, Bateman R, Morris JC, Vile RG. Gene therapy for prostate cancer: current status and future prospects. J Urol 2001;166:1220-33.
10. Eastham JA, Grafton W, Martin CM, Williams BJ. Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer. J Urol 2000;164:814-9.
11. Schumacher G, Bruckheimer EM, Beham AM, et al. Molecular determinants of cell death following adenovirus-mediated gene transfer of wild-type p53 in prostate cancer cells. Int J Cancer 2001;91:159-66.
12. Miyake H, Hanada N, Nakamura H, et al. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer. Oncogene 1998;18:3087-92.
13. Blaschuk O, Burdzy K, Fritz IB. Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid. J Biol Chem, 1983;258:7714-20.
14. Rosenberg ME, Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 1995;27:633-45.
15. Sensibar JA, Griswold MD, Sylvester SR, et al. Prostatic ductal system in rats: regional variation in localization of an androgen-repressed gene product, sulfated glycoprotein-2. Endocrinology 1991; 128:2091-102.
16. Connor J, Buttyan R, Olsson CA, D'Agati V, O'Toole K, Sawczuk I.S. SGP-2 expression as a genetic marker of progressive cellular pathology in experimental hydronephrosis. Kidney Int 1991;39:1098-103.
17. Kyprianou N, English HF, Davidson NE, Isaacs JT. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 1991;51:162-6.
18. Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990;50:3748-53.
19. Ho SM, Leav I, Ghatak S, Merk F, Jagannathan VS, Mallery K. Lack of association between enhanced TRPM-2/clusterin expression and increased apoptotic activity in sex-hormone-induced prostatic dysplasia of the Noble rat. Am J Pathol 1998;153:131-9.
20. Schwochau GB, Nath KA, Rosenberg ME. Clusterin protects against oxidative stress in vitro through aggregative and nonaggregative properties. Kidney Int 1998;53:1647-53.
21. French LE, Sappino AP, Tschopp J, Schifferli JA. Distinct sites of production and deposition of the putative cell death marker clusterin in the human thymus. J Clin Invest 1992;90:1919-25.
22. Sensibar JA, Sutkowski DM, Raffo A, et al. Prevention of cell death induced by tumor necrosis factor á in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). Cancer Res 1995;55:2431-7.
23. Steinberg J, Oyasu R, Lang S, et al. Intracellular levels of SGP-2 (clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res 1997;3:1701-11.
24. Sintich SM, Steinberg J, Kozlowski JM, et al. Cytotoxic sensitivity to tumor necrosis factor-α in PC3 and LNCaP prostatic cancer cells is regulated by extracellular levels of SGP-2 (clusterin). Prostate 1999;39: 87-93.
25. July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 2002;50:179-88.
26. Miyake H, Nelson C, Rennie PS, Gleave ME. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 2000;60: 170-6.
27. Miyake H, Nelson C, Rennie PS, Gleave ME. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res 2000;60:2547-54.
28. Miyake H, Chi KN, Gleave ME. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2000;6: 1655-63.
29. Gautschi O, Tschopp S, Olie RA, et al. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J Natl Cancer Inst 2001;93:463-71.
30. Miyake H, Tolcher A, Gleave ME. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Inst 2000;92: 34-41.
31. Kuroda H, Mandai M, Konishi I, et al. Human ovarian surface epithelial (OSE) cells express LH/hCG receptors, and hCG inhibits apoptosis of OSE cells via up-regulation of insulin-like growth factor-1. Int J Cancer 2001;92:309-15.
32. Sato N, Gleave ME, Bruchovsky N, Rennie PS, Beraldi E, Sullivan LD. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice. Cancer Res 1997; 57:1584-9.
33. Miyake H, Hara I, Kamidono S, Gleave ME. Synergistic chemosensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin Cancer Res 2001;7:4245-52.
34. Zellweger T, Miyake H, July LV, Akbari M, Kiyama S, Gleave ME. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the anti-apoptotic gene clusterin. Neoplasia 2001;3: 360-7.
35. Hara I, Miyake H, Gleave ME, Kamidono S. Introduction of clusterin gene into human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy through inhibition of apoptosis both in vitro and in vivo. Jpn J Cancer Res 2001;92:1220-4.
36. Crooke ST. Therapeutic applications of oligonucleotides. Annu Rev Pharmaco Toxicol 1992;32:329-76.
37. Wagner RW. The state of the art in antisense research. Nat Med 1995;1:1116-8.
38. Zellweger T, Miyake H, Cooper S, et al. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy) ethyl chemistry. J Pharmacol Exp Ther 2001;298:934-40.
39. Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against c-raf kinase. Nat Med 1996;2:668-75.
40. Cucco C, Calabretta B. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides. Cancer Res 1996;56:4332-7.
41. Miyake H, Tolcher A, Gleave ME. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. Cancer Res 1999;59:4030-4.
42. Miyake H, Pollak M, Gleave ME. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen-independence in prostate cancer models. Cancer Res 2000;60: 3058-64.
43. Navone NM, Labate ME, Troncoso P, Pisters LL, Conti CJ, von Eschenbach AC. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol 1999;161:304-8.
44. Raffo AJ, Periman H, Chen MW, Streitman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995;55:4438-45.
45. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or predonisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-64.
46. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with and without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999;17:2506-13.